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ABSTRAK 
Tajuk:  
Kesan modifikasi kawalan kalori selang sehari pada penyakit hati berlemak bukan di sebabkan 
alcohol. 
 
Latar belakang:  
Penyakit hati berlemak bukan disebabkan alkohol adalah punca kepada mortaliti dan morbiditi 
disebabkan oleh komplikasi kardiovaskular dan juga komplikasi berkaitan dengan hati. Pada 
masa ini, tiada rawatan yang berkesan untuk rawatan penyakit ini; pengurangan berat badan 
disyorkan. Modifikasi kawalan kalori selang sehari lebih mudah dilaksanakan berbanding 
kawalan kalori setiap hari, akan  tetapi, tiada kajian khusus yang telah dijalankan untuk melihat 
kesan pada penyakit ini khasnya  kepada perubahan pada fibrosis dan lemak di hati. 
 
Objektif:  
Tujuan  kajian ini adalah untuk menentukan kesan modifikasi kawalan kalori selang sehari pada 
perubahan lemak dan fibrosis di hati, anthropometri  dan juga perubahan biokimia dalam 
penyakit hati berlemak bukan disebabkan alkohol selepas 8 minggu modifikasi kawalan kalori 
selang sehari .  
 
Metod:  
Kami menjalankan satu kajian prospektif yang melibatkan pesakit-pesakit gastroenterologi yang 
menghidap penyakit hati berlemak bukan disebabkan alkohol. Kajian ini dijalankan di Hospital 
Universiti Sains Malaysia dari Ogos 2015 sehingga Julai 2016.   
 
xiv 
 
Keputusan:  
Seramai 105 pesakit telah disaring, 41 dipilih tetapi 11 menarik diri dan 30 peserta (minimun 
umur 43.9 tahun,  BMI 31.5kg / m2, lelaki 70%, kencing manis 53%) selesai kajian. Dengan 8 
minggu MACR, pengurangan ketara telah diperhatikan keatas gred steatosis hati (pengurangan 
40% dalam mereka yang mempunyai steatosis sederhana, P = 0.001), SWE (perbezaan purata 
0.9, P = 0.001), BMI (perbezaan purata 0.6 kg / m2 , P = 0.003), glukosa (perbezaan median 0.3 
mmol / L, P = 0.01), ALT (perbezaan median 20.5 U / L, P = 0.001) dan AST (perbezaan median 
9 U / L, P = 0.002) 
 
Kesimpulan:  
Kesimpulan, keputusan menunjukkan modifikasi kawalan kalori selang sehari boleh 
dilaksanakan sebagai strategi yang berkesan untuk penyakit hati berlemak bukan di sebabkan 
alkohol terutamanya ke atas pesakit dengan steatosis sederhana dan fibrosis hati peringkat awal. 
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ABSTRACT 
Title: 
The effect of modified alternate day calorie restriction (MACR) on non-alcoholic fatty liver 
disease (NAFLD) 
 
Background:  
Non-alcoholic fatty liver diseases are an important cause of morbidity and mortality due to 
adverse cardiovascular outcomes and also liver-related complications. Currently, there is no 
approved therapy for non-alcoholic fatty liver diseases; weight reduction is typically 
recommended. Modified alternate day calorie restriction is more feasible to the patient compared 
to daily calorie restriction; however, no trials have been done in non-alcoholic fatty liver diseases 
patients focusing on changes in liver fibrosis and steatosis. 
 
Objectives:  
The aim of this study is to evaluate the effect of modified alternate day calorie restriction on the 
changes in liver steatosis and fibrosis, anthropometry as well as biochemical parameters in non-
alcoholic fatty liver diseases patients after 8 weeks of modified alternate day calorie restriction.  
 
Methods:  
We performed a prospective study involving adult gastroenterology patients with non-alcoholic 
fatty liver disease from August 2015 to July 2016 in Hospital Universiti Sains Malaysia.  
 
 
 
xvi 
 
 
Results:  
A total of 105 patients were screened, 41 consented but 11 withdrew and 30 participants (mean 
age 43.9 years, BMI 31.5kg/m
2
, males 70%, diabetes 53%) completed the study. With 8 week 
MACR, significant reductions were observed of grading of liver steatosis (40% reduction in 
those with moderate steatosis, P=0.001), SWE (mean difference 0.9, P=0.001), BMI (mean 
difference 0.6 kg/m
2
, P=0.003), glucose (median difference 0.3 mmol/L, P=0.01), ALT (median 
difference 20.5 U/L, P=0.001) and AST (median difference 9 U/L, P=0.002) 
 
Conclusion: 
In summary, the results indicate that modified alternate day calorie restriction appear to be  an 
effective diet strategy to help reducing the risk of progression for non-alcoholic fatty liver 
diseases especially in patients with moderate steatosis and mild fibrosis.  
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CHAPTER 1: INTRODUCTION 
 
1.1   Non-alcoholic fatty liver disease (NAFLD) background 
 
Non-alcoholic fatty liver disease is a chronic liver disease [Angulo 2002] with 
a spectrum of disease from mild hepatic steatosis to liver necroinflammation and 
hepatocellular injury that lead to cirrhosis later, causing liver failure and 
hepatocellular carcinoma as well as cardiovascular complications [Alberti 2009]. 
Progression of non-alcoholic fatty liver disease is highly variable, only 2-3% will 
progress to end-stage liver disease. However, with the rising prevalence of insulin 
resistance/type 2 diabetes mellitus and obesity, non-alcoholic fatty liver disease 
become one of most frequent liver diseases [Almeda 2009]. The spectrum of non-
alcoholic fatty liver disease is shown in Figure 1.0.  
stimation 
Figure 1.0   Spectrum of non-alcoholic fatty liver disease (Adapted from D 
Schuppan and JM Schattenberg 2013)  
 
 
To diagnose non-alcoholic fatty liver disease is based on the presence of 
hepatic steatosis either via imaging or histology and no secondary cause for fat 
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accumulation such as alcohol consumption, use of steatogenic medication or 
hereditary disorder. Metabolic factor such as type II diabetes mellitus, obesity and 
dyslipidemia are commonly associated with non-alcoholic fatty liver disease [Alberti 
2009].  
 
Histologically, non-alcoholic fatty liver disease can be further categorized into 
two groups; non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis 
(NASH). The presence of hepatic steatosis with no evidence of hepatocellular injury 
in the form of ballooning of hepatocytes is defined as non-alcoholic fatty liver and if 
there is inflammation with ballooning of hepatocyte injury with or without fibrosis is 
defined as non-alcoholic steatohepatitis [Vernon 2011]. 
 
Non-alcoholic fatty liver disease is considered to be a benign condition with 
the absence of significant fibrosis; however with the presence of fibrosis [Ekstedt 
2006] it does predict both disease progression and liver-related complications over a 
subsequent 10-year period [D Schuppan 2013]. Cardiovascular causes are 
predominantly leading to an increased mortality rate with a significant increase in 
liver-related deaths. Increase incidence of hepatocellular carcinoma in type 2 diabetes 
mellitus is due to high prevalence of NASH where NASH carries an increased risk for 
hepatocellular carcinoma [Ekstedt 2006]. 
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Table 1.0 Prevalence of T2DM, obesity, and hypertriglyceridemia in NAFLD 
(Adapted from McCullough 2002) 
 
 
1.2   Pathogenesis of Nonalcoholic fatty liver disease 
Figure 1.1  Pathomechanisms during the progression of NAFLD (Adapted 
from D Schuppan 2013) 
 
 
Pathogenesis of non-alcoholic fatty liver disease is initially based on the ‘2 hit 
hypothesis’. Hepatic triglyceride accumulation/steatosis is considered as ‘the first hit’ 
leading to the susceptibility of the liver to injury mediated by ‘second hit’ such as 
oxidative stress, inflammatory cytokines/adipokines and mitochondrial dysfunction 
[D Schuppan 2013]. ‘The second hit’ leads to steatohepatitis and/or fibrosis. Due to 
the recognitions the role of free fatty acid (FFA) that plays a role in promoting liver 
injury, there has been a modification to this theory. In obese and insulin resistance 
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patients, there were influxes of free fatty acid to the liver which either undergoes b-
oxidation or are esterified with glycerol to form triglycerides, causing accumulation 
of hepatic fat [Feldstein AE 2004]. FFA can directly cause toxicity by activation of 
inflammatory pathways leading to increasing oxidative stress. However, hepatic 
triglycerides can be a protective mechanism via preventing the toxic effect of 
unesterified FFA [Yamaguchi 2007].  A ‘third hit’ has been added to reflect 
inadequate hepatocyte proliferation via oxidative stress that inhibits the replication of 
mature hepatocytes, leading to expansion of hepatic progenitor cell (oval) populations 
[Joi J 2007]. Later, these cells differentiate into hepatocytes like-cell, and both oval 
cell and intermediate hepatocytes-like cell number that predominantly correlate with 
fibrosis stage. These suggest that the cumulative hepatocyte-like cell will promote 
both accumulation of progenitor cell and differentiation toward hepatocytes [Roskams 
T 2003]. Hepatocellular carcinogenesis will occur with activations of these cells. The 
development of fibrosis/cirrhosis depends on the efficacy of regeneration of 
hepatocyte with the impaired proliferation of progenitors will represent ‘the third hit’ 
in NAFLD pathogenesis [Joi J 2007]. 
 
1.3   Prevalence and natural history of non-alcoholic fatty liver disease 
 
Differences in methods used to diagnose the various stages of non-alcoholic 
fatty liver disease leads to the variable estimation of prevalence. Histology features of 
NAFLD may be indistinguishable from alcoholic liver disease thus requiring 
exclusion of known excessive alcoholic intake. 
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International data 
 
Screening studies in western countries using liver chemistry and 
ultrasonography suggest the prevalence of non-alcoholic fatty liver disease were 
ranging from 17% to 33% in the general population [Clark JM 2003]. Prevalence of 
non-alcholic fatty liver disease is increased to 34% when using magnetic resonance 
spectroscopy (MRS) [Browning JD 2004]. Prevalence of non-alcoholic steatohepatitis 
is less well known due to liver biopsy is required to confirm the diagnosis, with an 
estimated prevalence of approximately 3% in the general population; higher in obese 
persons [Wanless IR 1990].  
 
Natural history 
 
There are limited data looking at the natural history and progression of non-
alcoholic fatty liver disease from simple steatosis to advanced fibrosis mainly due to 
limited number patients undergoing liver biopsies in follow-up studies. Investigation 
and methods to diagnose non-alcoholic fatty liver disease such as blood tests, 
ultrasound and liver biopsy (gold standard) [Clark JM 2003] are not uniform and 
long-term complication  of NAFLD may be under-reported, as steatosis may 
disappear in the late stage of disease leading to a picture of ‘bland’ cirrhosis, 
commonly known as ‘cryptogenic’ rather than NAFLD-related disease. NAFLD have 
been recognized as the most common cause of cryptogenic cirrhosis [Clark JM 2003].  
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Figure 1.2 The natural history of NAFLD. (Adapted from Preiss and Satta 2008, 
McCullough 2002] 
 
 
As a result, the majority of studies to date that have studied the natural history 
of non-alcoholic fatty liver disease are mainly retrospective analyses or case series in 
which selected patient with NASH underwent subsequent liver biopsy. It is difficult to 
identify the proportion of an unselected population who will progress to NAFLD-
related cirrhosis and later hepatocellular carcinoma (HCC). Approximately 7% of 
cases of hepatocellular carcinoma were related to underlying NAFLD/cryptogenic 
cirrhosis [Clark JM 2003]. 
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Associations with type 2 diabetes mellitus and obesity  
 
The presence of type 2 diabetes mellitus leads to an increased risk and severity 
of non-alcoholic fatty liver disease [Targher 2007] and numerous trials have reported 
an increased prevalence of non-alcoholic fatty liver disease in patients with type 2 
diabetes mellitus [William RM 2009]. Up to 73.9% of subjects were found to have 
ultrasound-detected steatosis in 939 randomly selected people with type 2 diabetes 
mellitus in Edinburgh and in obese patients; the prevalence of non-alcoholic fatty 
liver disease is high up to 80% [Clark JM 2003]. The incidence and prevalence of 
type 2 diabetes mellitus and obesity is increasing in the world population leading to 
an increasing incidence and prevalence of fatty liver and hence non-alcoholic 
steatohepatitis is more likely to increase [Gonzalez ELM 2009]. 
 
Cardiovascular risk  
 
NAFLD has been linked with increased cardiovascular complications, likely 
through the component of the metabolic syndrome which leads to an increased 
incidence of morbidity and mortality. Ghouri et al reported the presence of non-
alcoholic fatty liver disease, where it is an indication for screening for type 2 diabetes 
mellitus, however there was no added data on cardiovascular risk as compared with 
traditional risk factors. Thus, it showed that non-alcoholic fatty liver disease was not 
an independent contributor to cardiovascular risk but it was related to adverse risk 
factors. A review by Targer et al mentioned the questions of whether or not non-
alcoholic fatty liver disease increased cardiovascular disease with independent 
association with traditional risk factor. These observations raised the possibility that 
non-alcoholic fatty liver disease; especially with the presence of necro-inflammation, 
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may be involved in the pathogenesis of cardiovascular disease in addition to acting as 
a marker of cardiovascular disease. It may occur through the pro-atherogenic 
mediator that is released in the systemic circulation from a steatotic and inflamed 
liver, or through insulin resistance and atherogenic dyslipidemia contributed by non-
alcoholic fatty liver disease. The important issue highlighted by Targher et al was that 
in people with non-alcoholic fatty liver disease, cardiovascular disease is greater 
threat than liver disease. 
1.4   Clinical presentation 
 
Clinical presentation depends on the stage of presentation of liver damage as 
we know that non-alcoholic fatty liver disease is a spectrum of liver damage; from 
mild steatosis to advanced liver fibrosis that leads to liver cirrhosis and hepatocellular 
carcinoma. The patient is often asymptomatic and usually detected following 
investigations of abnormal liver function test results. Symptoms if present may 
include fatigue and right upper quadrant pain and clinical finding of hepatomegaly 
[Sanyal AJ 2002]. Symptoms will be more prominent in people with cirrhosis, 
patients have clinical signs including ascites, variceal bleeding, splenomegaly, bruised 
and jaundice. 
 
1.5   Diagnosis of non-alcoholic fatty liver disease 
 
Based on clinical history and ultrasound, non-alcoholic fatty liver disease can 
be reasonably diagnosed,  however it is difficult to stage non-alcoholic fatty liver 
disease and as for the current consensus for NASH; it can be diagnosed only after 
liver biopsy (gold standard). This would be a major hindrance to conducting a trial 
that requires a large number of patients for NASH.  
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Laboratory and radiological methods used to diagnose non-alcoholic fatty 
liver disease are either too insensitive or not specific to grade severity and stage it. In 
early steatosis, the patient is often asymptomatic and only elevated liver enzymes are 
the only clue to the presence of the disease. Although alanine aminotransferase (ALT) 
levels could be used as a reliable biochemical marker to correlate hepatic steatosis, 
however, up to 70% of non-alcoholic fatty liver disease patients may have normal 
liver enzymes [Mofrad P 2003] and it is unable to distinguish between varying stages 
of non-alcoholic fatty liver disease. In histologically severe disease, ALT level could 
be normal. An imaging method using ultrasound is recommended as a first-line 
investigations to detect the presence of hepatic steatosis [Ratziu V 2010]. Magnetic 
resonance spectroscopy (MRS) has a high sensitivity in detecting and quantifying 
hepatic steatosis, however, both ultrasound and MRS are not able to detect 
inflammation and /or fibrosis in NASH.  
 
At present, the gold standard to diagnose non-alcoholic fatty liver disease and 
staging the degree of inflammation and fibrosis by histological assessment and to 
monitor the progression of non-alcoholic fatty liver disease is still liver biopsy 
[Kleiner DE 2005]. However, the limitations of liver biopsy are that it is invasive. As 
a response to this, multiple algorithms combining clinical and specialized biomarkers 
with an imaging method which uses liver elastography has been developed, this 
allows the use of non-invasive testing to detect inflammation/fibrosis as well as 
staging of the disease. 
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1.6   Biochemical picture associated with non-alcoholic fatty liver disease 
 
Alanine transaminase (ALT) and aspartate transaminase (AST) are part of a 
group of liver function tests.  In a patient with cirrhosis, AST concentration is higher 
than ALT and in patients with non-alcoholic fatty liver disease, if AST is raised 
leading to a reversal of the ALT/AST ratio, it is potentially a marker of poor 
prognosis, suggesting of liver cell death with inflammation (necrosis) [Preiss D 2008].  
 
Predicting non-alcoholic fatty liver disease 
 
Factors such as age, BMI, hypertriglyceridemia and elevated liver chemistry 
are independent risk factors for liver fibrosis. There are also non-invasive scoring 
systems that combine clinical as well as blood parameters which could be used to 
predict the stage of non-alcoholic fatty liver disease especially for advanced fibrosis 
stages [Ratviu V 2000]. Liver biopsy is an invasive procedure which may be 
associated with a number of complications and error in sampling, expertise is also 
needed to interpret the sample. This had led to efforts to find a non-invasive 
biomarker for fibrosis in patients with non-alcoholic fatty liver disease. 
 
Clinical scoring systems is based on simple clinical and laboratory parameters 
have been suggested to assess the presence of advanced fibrosis in patients with 
NAFLD as well another liver diseases. These include, aspartate/ alanine 
aminotransferase (AST/ALT) ratio [William AL 1988], aspartate aminotransferase-to-
platelet ratio (APRI) [Wai CT 2003], Fibrosis-4 (FIB-4) score [Vallet-Pichard A 
2007], BARD score [Harrison SA 2008] and NAFLD fibrosis score [Angulo P 2007].   
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All these simple scoring systems showed high negative predictive value 
(NPV) in the cohort of NAFLD patient with advanced fibrosis and this suggests, 
simple scoring systems can be used clinically as tools to exclude patients with 
advanced fibrosis. Liver biopsy can be avoided in 69% of NAFLD patients in the 
cohort and up to 93% have been classified correctly using the simplest scoring 
system; the AST/ALT ratio (<0.8).  Same goes to FIB-4 and NAFLD fibrosis score, 
liver biopsy can be avoided in half of the NAFLD patient as shown in table 1.1. 
 
Table 1.1   Proportion of patients who may potentially avoid liver biopsy using 
the simple non-invasive tests to exclude advanced fibrosis (Adapted from Angulo 
P 1999) [41] 
 
 
 
The use of these non-invasive scoring systems may substantially reduce the 
number of patients who undergo liver biopsies and can direct liver biopsy to those 
who have likely advanced fibrosis. However, in contrast to the negative predictive 
value, the positive predictive value for each scoring system is ranging from 27%-79% 
is inaccurate to be used to diagnose advanced fibrosis. As a conclusion, these simple 
scoring systems can be reliably used to exclude advanced fibrosis in NAFLD and can 
reduce the number of patients with mild disease undergoing liver biopsy [S 
McPherson 2010]. 
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1.7   Imaging modalities 
 
Liver biopsy is still the gold standard for diagnosis as well as to stage NAFLD 
patients and monitor the progression of the disease, however, imaging methods have 
gained acceptance as the non-invasive alternative to liver biopsy. Cost effective and 
well established imaging techniques of ultrasonography for diagnosis of hepatic 
steatosis is beneficial especially for screening in a large population who are at risk for 
NAFLD [Lee SS 2010].  It has a reliable and reasonable accuracy in detecting 
moderate to severe hepatic steatosis, however it is limited by operator-dependent 
issues as well as being less accurate in detecting mild hepatic steatosis and is rather 
qualitative [Palmenteri B 2006]. Computed tomography in assessing hepatic steatosis 
for the general population is not appropriate due to its inaccuracy in detecting mild 
hepatic steatosis and also is a potential radiation hazard. Other imaging modalities 
such as magnetic resonance spectroscopy and magnetic resonance imaging are the 
most accurate imaging methods in measuring hepatic steatosis which can directly 
measure the quantity of hepatic fat [Reeder SB 2011]. 
 
Liver steatosis grading using ultrasound modalities 
 
Imaging modalities using ultrasonography allows for accuracy and reliability 
to detect the presence of moderate-severe fatty liver. Benefits are in terms of safety, 
low cost and easy accessibility; this imaging technique is a reliable choice for 
screening NAFLD in clinical and population settings.  Hepatic steatosis is graded 
from 0-3 based on visual analysis of the intensity of the echogenicity with appropriate 
gain setting [Dhumal 2013]. 
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Fat infiltration in the liver is described in 4 ultra-sonographic grades.  
 
Normal liver parenchymal (Grade 0) 
With the same kidney cortex and liver parenchyma echogenicity it is evaluated as 
normal, no fatty liver  
 
Figure 1.3 Normal liver parenchymal (Adaptation from Dhumal Uttareshvar 
Mahaling 2013) 
 
Mild (Grade 1) 
Increased liver echogenicity and liver-kidney contrast where liver appears bright 
compared to the cortex of the kidney. Normal visualization of diaphragm and 
intrahepatic vessel borders  
 
Figure 1.4 Grade 1 liver steatosis. (Adaptation from Dhumal Uttareshvar 
Mahaling 2013)  
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Medium (Grade 2) 
Increased liver echogenicity and liver-kidney contrast and blurring of peripheral 
portal vein margins and slight deep attenuation. Slightly impaired visualization of the 
intrahepatic vessels and diaphragm 
 
Figure 1.5   Grade 2 Liver steatosis. (Adaptation from Dhumal Uttareshvar 
Mahaling 2013)  
 
 
Severe (Grade 3) 
Increased liver echogenicity and liver-kidney contrast with non-visualisation of portal 
vein margins, the diaphragm and posterior part due to deep attenuation of ultrasound. 
Poor or no visualization of intrahepatic vessels and diaphragm with poor penetration 
of the posterior segment of the right lobe of the liver. 
 
 
Figure 1.6  Grade 3 Liver steatosis. (Adaptation from Dhumal Uttareshvar 
Mahaling 2013)  
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The ratio between the mean brightness level of the liver and right kidney 
(hepatorenal sonographic index); proposed as a measure of hepatic steatosis with high 
sensitivity (100%) and specificity (91%) for diagnosis of non-alcoholic fatty liver 
disease (steatosis more than 5%) [Webb M 2009]. Furthermore, it can be integrated 
with liver elastography to assess liver fibrosis. 
 
Imaging diagnosis for liver elastography 
 
The development of steatohepatitis in non-alcoholic fatty liver disease is a risk 
factor for liver cirrhosis and liver-related mortality; and it is important to detect the 
presence of steatohepatitis/necro-inflammation before it can progress to fibrosis and 
cirrhosis an end spectrum of non-alcoholic fatty liver disease [Adam LA 2005]. 
Ultrasound and magnetic resonance elastography can be used to evaluate liver 
stiffness by measuring the velocity of the shear wave. Several techniques for US 
elastography include transient elastography, acoustic radiation force impulse 
elastography, real-time elastography as well as a supersonic shear wave which differ 
in methods of shear wave generation and /or detection. These have had been used to 
evaluate liver stiffness/fibrosis in patients with chronic viral hepatitis and recently its 
usage had been expanded to other liver diseases including non-alcoholic fatty liver 
disease.  
 
Ultrasound elastography techniques have shown excellent results in evaluating 
the presence of liver fibrosis in non-alcoholic fatty liver disease [Fruhwirth R 2008]. 
As liver fibrosis increases; it will show a stepwise increase in liver stiffness and this 
has been highly accurate in differentiating advanced fibrosis from mild liver fibrosis. 
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The sensitivities and specificities of this modality are ranging from 88.9% to 100% 
and 75% to 100% respectively [Wong VW 2010].  
 
The degrees of hepatic steatosis or hepatic inflammation did not correlate with 
a value of liver stiffness [Wong VW 2010], indicating that ultrasound elastography 
may evaluate liver fibrosis associated with hepatic steatosis; however, it would not be 
able to assess hepatic inflammation [Giovanna F 2014]. 
 
Shear wave elastography (SWE)  
 
 Shear wave elastography (SWE) is a non-invasive method to assess liver 
tissue stiffness. It relies on the generation of shear waves that is determined by tissue 
displacement which is induced by an external force or ultrasound beam. These are 
lateral waves with a motion perpendicular to the direction of pressure that has 
generated them. The shear wave travels between 1 and 10m/s and rapidly is 
attenuated by tissue. The elasticity of tissue correlates with propagation velocity of 
shear waves i.e. it increases with increasing stiffness of liver tissue.  
 
A standard M probe is used in shear wave elastography and uses a 5-MHz 
ultrasound transducer mounted on the axis of a vibrator. It will generate a painless 
vibration with amplitude 2mm and 50 Hz frequency, propagated via skin and 
subcutaneous tissue into the liver and is directly related to liver tissue stiffness as 
shown in figure 1.8 [Giovanna F 2014]. 
 
17 
 
 
Figure 1.7 Schematic image showing physical principles of ultrasonographic 
shear wave elastography. (Adapted from Kema Arda 2013) 
 
 
1.8   Treatment of non-alcoholic fatty liver disease 
 
There are several effective therapies available despite understanding the 
pathogenesis of non-alcoholic fatty liver disease. Available treatments are focused 
towards improving metabolic parameters via focusing on weight loss and exercise, 
reducing insulin resistance by optimizing diabetic control. Others are therapies such 
as insulin sensitizers i.e. metformin and thiazolidinedione, weight loss drugs i.e. 
orlistat and sibutramine and consideration for bariatric surgery in morbidly obese 
patients; however none of them have been approved for general use for non-alcoholic 
fatty liver disease [Bugiianesi E 2002]. Even though the clinical trial of 
thiazolidinedione has shown positive results, however, the benefit from treatment is 
limited by side effects and complications of the drug, these limits widespread 
acceptance [Lutchman G 2007]. 
 
At the moment, there are no approved treatments, neither surgical nor medical 
therapy for non-alcoholic fatty liver disease. The aim of the treatment will depend on 
the stage of diagnosis is made as non-alcoholic fatty liver disease group. There is no 
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available trial that showed the outcome of treatment focusing on important long-term 
outcomes such development of cirrhosis or HCC.  
 
Even with a global epidemic and a growing understanding of non-alcoholic 
fatty liver disease, there is still no definite pharmacotherapy available. Lifestyle 
modification with dietary changes and regular exercise as well as bariatric surgery in 
the obese patient aiming for gradual weight loss have been proposed as beneficial 
treatment based on available evidence [G Musso 2010]. The mainstay of treatment is 
still weight loss and exercise. Sustained improvement in liver chemistry, histology 
(inflammation/fibrosis) and serum insulin level can be achieved by weight loss and 
physical activities; this is recommendation for all patients with NASH, especially 
those who are overweight/obese [Hill JO 1999]. 
 
Pharmacological therapies that may have benefit are anti-inflammatory or 
anti-oxidant agents. Insulin sensitizers such as thiazolidinedione and antioxidant such 
as vitamin E have a promising outcome, however, there are some issues for long-term 
safety as well as the adverse effects that have limit the use of this drug. However it 
can be used in addition to lifestyle modification. 
 
In addition, vitamin E combined with other agents may have better efficacy. 
Other pharmacotherapy such as pentoxifylline, ursodeoxycholic acid, and herbal 
medications may have potential therapeutic benefit although supporting evidence are 
inconclusive. 
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Lifestyles intervention 
 
Evidence for weight loss focusing on improving liver histology in non-
alcoholic fatty liver disease come from randomized control trials testing the effects of 
weight loss on nonalcoholic steatohepatitis; Pomrat et al have randomized 31 obese 
patients with NASH into intensive lifestyle changes over 48 weeks versus structured 
basic education only. The intensive group had shown significant improvement in 
steatosis, necrosis, and inflammation but not fibrosis. Harrison et al. showed a similar 
pattern where participants who had lost 5% body weight had improved steatosis, and 
in individuals with 9% weight loss there was significant improvement in steatosis, 
lobular inflammation, ballooning and NAS. 
 
Daily calorie restriction is the commonest form of dietary restriction that is 
currently implemented. However even though daily calorie restriction has proven to 
be an effective weight loss regime especially in the obese population, people find it 
difficult to adhere to this strategy of weight loss [Pomprat K 2010]. Intermittent 
calorie restriction was invented to achieve weight loss by improving adherence with 
these protocols, as intermittent calorie restriction is only required every other day 
compared to conventional ways of daily calorie restriction [Varady KA 2007]. 
Intermittent calorie or also known as alternate day fasting is divided into two 
components, a ‘feed day’ and ‘fast day’ where food is consumed ad libitum over a 24 
hours period alternating with either complete or partially restriction over 24 hours. 
There is also another form of intermittent calorie restriction which is 2 to 4 days of ad 
libitum feeding alternating with to 2-4 days of fasting or calorie restriction which 
could also be implemented.  
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1.9   Rationale of the study 
 
The dilemma in managing non-alcoholic fatty liver disease is difficulty in 
staging the patient with non-alcoholic fatty liver disease due to invasive nature of 
liver biopsy itself, there is no approved pharmacological therapy for non-alcoholic 
fatty liver disease. Strong recommendations mainly focus on controlling risk factors 
and lifestyle intervention with physical exercise showing excellent results.  
 
The most common diet strategies are daily calorie restriction involving 
restriction of energy intake every day by 20-50% [Omedei D 2011] of daily 
requirement per individual. However, limitation in this regime is many people find 
this type of dieting difficult, as vigilant calorie counting on a daily basis is required. 
Many people grow frustrated with this diet, as they are unable to eat freely throughout 
the day in the long run. 
 
The important factor in lifestyle intervention is that sustainable and effective 
energy restriction strategies are required. Intermittent calorie restriction/fasting are 
one of the possible approaches reducing calorie requirement per day. It is a short spell 
of severe restriction between longer periods of habitual energy intake. This approach 
is much easier subject for the to comply compared to daily or continuous energy 
restriction (CER). However, intermittent calorie restriction itself have multiple 
variations in term of total calorie per day i.e. 25%, 30% and up to 40% per day, 
interval time of calorie restriction and also type of food i.e. polysaturated/ 
monosaturated fat and also variation in term of duration of calorie restriction. 
Furthermore, no specific trials have been done to evaluate effect of alternate day 
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calorie restriction in liver steatosis and fibrosis in non-alcoholic fatty liver disease 
patients. 
 
By doing this study, we will able to document any significant effect of the 8 
weeks modified alternate day calorie restriction which only allowed 30% of 
individual daily requirement of calorie per day in non-alcoholic fatty liver disease 
patients by evaluating the change of liver steatosis and fibrosis and also biochemical 
changes (lipid profile, fasting glucose, liver enzymes). 
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CHAPTER 2: OBJECTIVES 
 
2.1   General Objective 
The aim of this study was to evaluate the effect of 8 weeks modified alternate 
day calorie restriction on radiological changes in ultrasound of the liver and 
biochemical changes in patient with non-alcoholic fatty liver disease. 
 
2.2   Specific objectives and hypothesis 
Objective 1 
Inferential Statistics 
To compare differences in the median changes of liver steatosis after 8 weeks of 
modified alternate day calorie restriction in non-alcoholic fatty liver disease patients. 
Research question:  
Is there a difference in the mean of liver steatosis before and after 8 weeks of 
modified alternate day calorie restriction in non-alcoholic fatty liver disease patients?  
Null and alternative hypothesis: 
H0: There is no difference in mean of liver steatosis before and after the modified 
alternate day calorie restriction in non-alcoholic fatty liver disease patients.  
Ha: There is a difference in mean of liver steatosis before and after the modified 
alternate day calorie restriction in non-alcoholic fatty liver disease patients.  
23 
 
Objective 2 
Inferential Statistics 
To compare liver elasticity using shear wave elastography (SWE) during pre and post-
modified alternate day calorie restriction in non-alcoholic fatty liver disease patients. 
Research question:  
Is there a difference in the mean of liver elastography value before and after 8 weeks 
of modified alternate day calorie restriction in non-alcoholic fatty liver disease 
patients? 
Null and alternative hypothesis: 
H0: There is no difference in mean of liver elastography before and after the modified 
alternate day calorie restriction in non-alcoholic fatty liver disease patients.  
Ha: There is a difference in mean of liver elastography before and after the modified 
alternate day calorie restriction in non-alcoholic fatty liver disease patients 
 
Objective 3 
Inferential Statistics 
To compare differences in the mean of metabolic parameters (lipid profile, BMI, 
blood pressure, waist circumference and fasting blood glucose) after 8 weeks of 
modified alternate day calorie restriction in non-alcoholic fatty liver disease patients.  
Research question:  
Is there a difference in the mean of metabolic parameters (lipid profile, BMI, blood 
pressure, waist circumference and fasting blood glucose) after 8 weeks of modified 
alternate day calorie restriction in non-alcoholic fatty liver disease patients? 
 
 
24 
 
Null and alternative hypothesis: 
H0: There is no difference in mean of the metabolic parameters (lipid profile, BMI, 
blood pressure, waist circumference and fasting blood glucose) before and after the 
Modified Alternate Day Calorie Restriction in non-alcoholic fatty liver disease 
patients. 
Ha: There is a difference in mean of the metabolic parameters (lipid profile, BMI, 
blood pressure, waist circumference and fasting blood glucose)  before and after the 
modified alternate day calorie restriction in non-alcoholic fatty liver disease patients. 
 
Objective 4 
Inferential Statistics 
To compare differences in the mean of liver enzymes AST and ALT after 8 weeks of 
modified alternate day calorie restriction in non-alcoholic fatty liver disease patients 
Research question:  
Is there a difference in the mean of liver enzymes AST and ALT before and after 8 
weeks of modified alternate day calorie restriction in non-alcoholic fatty liver disease 
patients?  
Null and alternative hypothesis: 
H0: There is no difference in mean of liver enzymes AST and ALT before and after 
the modified alternate day calorie restriction in non-alcoholic fatty liver disease 
patients.  
Ha: There is a difference in mean of liver enzymes AST and ALT before and after the 
modified alternate day calorie restriction in non-alcoholic fatty liver disease patients.  
 
 
 
